• AngioDynamics’ NanoKnife IRE gained a Medicare coverage framework under Palmetto GBA’s final LCD L40205, effective July 5, 2026.
• Coverage applies to favorable intermediate-risk prostate cancer (grade group 2) and metastatic colorectal cancer to the liver in select cases.
• The decision supports reimbursement access in Palmetto GBA jurisdictions, a key step toward broader payer adoption.
• Category I CPT codes for IRE in prostate and liver procedures take effect Jan. 1, 2026, enabling standardized billing with RVUs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260528366815) on May 28, 2026, and is solely responsible for the information contained therein.